beta

ADAP

Adaptimmune Therapeutics plc

Adap

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Adaptimmune Therapeutics PLC along with its subsidiaries is a clinical-stage biopharmaceutical company. It is engaged in novel cancer immunotherapy products based on its T-cell receptor platform.

Market Cap: 855 Million

Primary Exchange: Nasdaq Global Select

Website: http://www.adaptimmune.com

Shares Outstanding: 93.7 Million

Float: 61.3 Million

Dividend: 0.0 (0.0%)

Beta: 1.894462

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 1.59 Million

Ethical Flags

Animal testing

Longest drawdown: 1100 trading days

From: 2015-06-16 To: 2019-10-18

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud